Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Up 1,180.8% in July

Avalon GloboCare Corp. (NASDAQ:ALBT) was the target of a significant growth in short interest in July. As of July 15th, there was short interest totaling 1,541,639 shares, a growth of 1,180.8% from the June 30th total of 120,361 shares. Based on an average trading volume of 4,865,720 shares, the short-interest ratio is currently 0.3 days. Currently, 14.0% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Avalon GloboCare from a “sell (e+)” rating to a “sell (e)” rating in a research report on Monday, June 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Avalon GloboCare Stock Performance

Avalon GloboCare has a 12-month low of $0.21 and a 12-month high of $4.74. The stock’s fifty day moving average is $0.32 and its two-hundred day moving average is $0.57. The company has a market capitalization of $4.05 million, a price-to-earnings ratio of -0.08 and a beta of -0.03.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.